Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 23, Number 9—September 2017

Dispatch

Evaluation of 5 Commercially Available Zika Virus Immunoassays

David SafronetzComments to Author , Angela Sloan, Derek R. Stein, Emelissa Mendoza, Nicole Barairo, Charlene Ranadheera, Leanne Scharikow, Kimberly Holloway, Alyssia Robinson, Maya Traykova-Andonova, Kai Makowski, Kristina Dimitrova, Elizabeth Giles, Joanne Hiebert, Rhonda Mogk, Sharla Beddome, and Michael Drebot
Author affiliations: Public Health Agency of Canada, Winnipeg, Manitoba, Canada

Main Article

Table 3

Detection of IgM in RT-PCR–positive serum samples by using in-house and commercial Zika virus serologic assays*

Sample collection dpo In-house Zika virus diagnostic results
DENV PRNT Commercial Zika virus serologic assays results
RT-PCR MAC-ELISA PRNT Euroimmun IgM Euroimmun IgG Novatec IgM Abcam IgM InBios IgM
0 Pos Neg ND ND Neg Neg Neg Neg Neg
2 Pos Neg ND ND Neg Neg Eq Neg Pos
5 Pos Neg ND ND Neg Neg Neg Neg Neg
7 Pos Pos ND ND Pos Pos Pos Pos Pos
3 Pos Neg ND ND Neg Neg Neg Neg Neg
2 Pos Neg ND ND Neg Neg Neg Neg Pos
2 Pos Pos ND ND Neg Neg Pos Neg Pos
3 Pos Neg ND ND Neg Neg Neg Neg Pos
3 Pos Neg ND ND Neg Neg Pos Neg PZ
2 Pos Neg ND ND Neg Neg Neg Neg Neg

*DENV, dengue virus; dpo, days postsymptom onset; Eq, equivalent; MAC-ELISA, IgM-capture ELISA; ND, not done; Neg, negative; Pos, positive; PRNT, plaque reduction neutralization test; PZ, possible Zika virus; RT-PCR, reverse transcription PCR.

Main Article

TOP